Enclomiphene for low testosterone: what week 1 won't tell you

What did @popethecoach actually say?

Not a lot, honestly. In a brief intro clip, @popethecoach announces he is starting "week one of TRT" combined with what he calls "Chlomophine" — almost certainly a mispronunciation of enclomiphene or clomiphene — and says he is "genetically low" with testosterone. He promises to document the journey and asks for a follow. That is the full extent of the medical content here.

To be fair, this is a week-one intro. There are no dosing claims, no cure claims, no wild promises about gains. The bar is low and he mostly clears it by saying almost nothing clinical at all. The things worth examining are the terminology slip and the phrase "genetically low," which deserves a closer look.

Does the science back this up?

The science on enclomiphene as a treatment for hypogonadism is real, though still maturing. Enclomiphene is not the same drug as clomiphene, which matters clinically and legally.

Clomiphene citrate is a mixture of two isomers: zuclomiphene and enclomiphene. Enclomiphene is the trans-isomer and works as a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus, prompting the pituitary to release more LH and FSH, which in turn stimulates endogenous testosterone production. A 2013 trial by Kim et al. in the Journal of Urology found enclomiphene raised serum testosterone in men with secondary hypogonadism while preserving sperm parameters, something exogenous testosterone does not do. A 2019 study by Wiehle et al. in the International Journal of Andrology confirmed similar findings over longer follow-up periods.

The distinction from traditional TRT is significant. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, shrinking testicular volume and reducing sperm production. Enclomiphene does the opposite. Whether a creator is actually using enclomiphene versus clomiphene versus something else entirely is something only their prescribing clinician can verify.

What did they get wrong (or right)?

The mispronunciation of enclomiphene as "Chlomophine" is worth flagging, not to be pedantic, but because these are pharmacologically distinct compounds being discussed in a health context with 4,400 viewers. Clomiphene and enclomiphene are not interchangeable terms, and the hashtag says enclomiphene, so presumably that is what he means.

The bigger claim worth scrutinizing is "genetically low with testosterone." This framing is common in fitness communities and sometimes accurate, but it requires precision. Primary hypogonadism, where the testes themselves underperform, can have a genetic component, as seen in Klinefelter syndrome. Secondary hypogonadism, which is what enclomiphene is designed to address, is typically a signaling problem at the hypothalamus or pituitary level, not a direct genetic defect. Using enclomiphene actually implies secondary hypogonadism, since the treatment works by stimulating the HPG axis. So the "genetically low" framing and the enclomiphene treatment choice are slightly at odds without more clinical detail. That does not make either wrong on its own, but it is imprecise language that could mislead viewers into thinking low testosterone is always a fixed genetic fate rather than often a treatable signaling issue.

What should you actually know?

If you are watching someone document a TRT or enclomiphene journey on TikTok, a few things are worth keeping straight before you take any of it as a model for your own health decisions.

• Enclomiphene is not FDA-approved as a standalone drug for male hypogonadism as of 2024. It is frequently prescribed off-label or obtained through compounding pharmacies. The FDA issued a warning in 2023 regarding compounded enclomiphene, noting it is not an approved drug and compounded versions lack the safety and efficacy data of an FDA-reviewed product. That does not mean it is dangerous, but it means the regulatory framework is unsettled.
• Low testosterone is diagnosed by clinical symptoms plus lab values, typically two morning total testosterone readings below 300 ng/dL per the American Urological Association guidelines. "Genetically low" is not a diagnosis.
• Week-one TRT content is almost never clinically informative. Testosterone levels, whether boosted endogenously or delivered exogenously, take weeks to reach stable levels. Any subjective energy or mood reports in week one are largely placebo effect territory, a real phenomenon but not a signal about the drug's efficacy.
• Enclomiphene preserves fertility in a way that injectable testosterone does not. For men who want biological children, this distinction is not minor. Matsumoto and colleagues have published extensively on the gonadotoxicity of exogenous androgens, and it is well-established.

Following someone's week-one intro is fine entertainment. It should not replace a conversation with a board-certified urologist or endocrinologist who has seen your labs.